Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma

Biochemical and Biophysical Research Communications

Volumn 439, Issue 4, 2013, Pages 586-590

  Xu, Jie ^a   Zeng, Li Fan ^a   Shen, Weihua ^a   Turchi, John J ^a   Zhang, Zhong Yin ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; EGFR; Lung cancer; Phosphatase inhibitor; SHP2

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; II B08; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

DRUG RESISTANCE; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERK; EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASE; LUNG CANCER; PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PTP; SHP2; SRC HOMOLOGY 2 (SH2)-DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; PYRONIA TITHONUS;

EID: 84884703820     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.09.028     Document Type: Article

References (29)

1. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 2009, 21:140-146.
2. Tonks N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006, 7:833-846.
3. Cohen P., Alessi D.R. Kinase drug discovery - what's next in the field?. ACS Chem. Biol. 2013, 8:96-104.
4. Zhang Z.Y. Protein tyrosine phosphatases: prospects for therapeutics. Curr. Opin. Chem. Biol. 2001, 5:416-423.
5. Julien S.G., Dubé N., Hardy S., Tremblay M.L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 2011, 11:35-49.
6. Jiang Z.X., Zhang Z.Y. Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev. 2008, 27:263-272.
7. Neel B.G., Gu H., Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 2003, 28:284-293.
8. Matozaki T., Murata Y., Saito Y., Okazawa H., Ohnishi H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 2009, 100:1786-1793.
9. Tartaglia M., Gelb B.D. Noonan syndrome and related disorders: genetics and pathogenesis. Annu. Rev. Genomics Hum. Genet. 2005, 6:45-68.
10. Tartaglia M., Niemeyer C.M., Fragale A., Song X., Buechner J., Jung A., Hahlen K., Hasle H., Licht J.D., Gelb B.D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 2003, 34:148-150.
11. Tartaglia M., Martinelli S., Cazzaniga G., Cordeddu V., Iavarone I., Spinelli M., Palmi C., Carta C., Pession A., Arico M., Masera G., Basso G., Sorcini M., Gelb B.D., Biondi A. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004, 104:307-313.
12. Bentires-Alj M., Paez J.G., David F.S., Keilhack H., Halmos B., Naoki K., Maris J.M., Richardson A., Bardelli A., Sugarbaker D.J., Richards W.G., Du J., Girard L., Minna J.D., Loh M.L., Fisher D.E., Velculescu V.E., Vogelstein B., Meyerson M., Sellers W.R., Neel B.G. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004, 64:8816-8820.
13. Miyamoto D., Miyamoto M., Takahashi A., Yomogita Y., Higashi H., Kondo S., Hatakeyama M. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic Ras-like transforming activity from solid tumors. Oncogene 2008, 27:3508-3515.
14. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., Stegh A.H., Bradner J.E., Ligon K.L., Brennan C., Chin L., DePinho R.A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
15. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Eastern cooperative oncology group, comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346:92-98.
16. Arteaga C.L. ErbB-targeted therapeutic approaches in human cancer. Exp. Cell Res. 2003, 284:122-130.
17. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
18. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
19. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101:13306-13311.
20. Yun C.H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M., Eck M.J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11:217-227.
21. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J.J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
22. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., Majem M., Lopez-Vivanco G., Isla D., Provencio M., Insa A., Massuti B., Gonzalez-Larriba J.L., Paz-Ares L., Bover I., Garcia-Campelo R., Moreno M.A., Catot S., Rolfo C., Reguart N., Palmero R., Sánchez J.M., Bastus R., Mayo C., Bertran-Alamillo J., Molina M.A., Sanchez J.J., Taron M. Spanish lung cancer group, screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 2009, 361:958-967.
23. Zhang X., He Y., Liu S., Yu Z., Jiang Z.X., Yang Z., Dong Y., Nabinger S.C., Wu L., Gunawan A.M., Wang L., Chan R.J., Zhang Z.Y. Salicylic acid-based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J. Med. Chem. 2010, 53:2482-2493.
24. Mali R.S., Ma P., Zeng L.F., Martin H., Ramdas B., He Y., Sims E., Nabinger S., Ghosh J., Sharma N., Munugalavadla V., Chatterjee A., Li S., Sandusky G., Craig A.W., Bunting K.D., Feng G.S., Chan R.J., Zhang Z.Y., Kapur R. Role of SHP2 phosphatase in KIT induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT. Blood 2012, 120:2669-2678.
25. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
26. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
27. Yamauchi K., Milarski K.L., Saltiel A.R., Pessin J.E. Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling. Proc. Natl. Acad. Sci. USA 1995, 92:664-668.
28. Marquardt B., Frith D., Stabel S. Signalling from TPA to MAP kinase requires protein kinase C, Raf and MEK: reconstitution of the signalling pathway in vitro. Oncogene 1994, 9:3213-3218.
29. Ueda Y., Hirai S., Osada S., Suzuki A., Mizuno K., Ohno S. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent of Raf. J. Biol. Chem. 1996, 271:23512-23519.